Ovid Therapeutics Inc.: management transactions · United States · SEC (Form 4)

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. (NASDAQ: OVID) is a United States-based biopharmaceutical company listed on the NASDAQ market and headquartered in New York, United States. Founded in 2014 and operational since that year, Ovid focuses on small-molecule medicines for brain disorders, particularly conditions driven by neuronal hyperexcitability and impaired excitatory/inhibitory balance. The company is best understood as a clinical-stage neuroscience biotech: it has no broad commercial product base, and its valuation is primarily driven by pipeline execution, clinical readouts, regulatory progress, and financing discipline. Ovid’s current strategy is centered on a differentiated neuroscience platform. Its lead development program, OV329, is a next-generation GABA-aminotransferase inhibitor being developed primarily for drug-resistant epilepsies and related seizure disorders. Management has reported encouraging early clinical data, including favorable safety, tolerability, pharmacokinetic, and pharmacodynamic findings, supporting advancement into later-stage studies. The company has also expanded OV329 into additional seizure-related indications, including tuberous sclerosis complex seizures and infantile spasms, which broadens the commercial opportunity while keeping the development theme focused on high unmet need. A second strategic pillar is the KCC2 portfolio. Ovid is advancing OV4071, an oral direct activator of the KCC2 transporter, as a potential first-in-class approach aimed at restoring inhibitory tone in the brain. The company’s KCC2 thesis is mechanistic and differentiated: rather than simply treating symptoms, it seeks to address a core biological control point in disorders where hyperexcitability and circuit dysfunction are central. Ovid also used OV350, an intravenous KCC2 direct activator, as a human proof-of-concept and target-validation program, providing clinical support for the broader KCC2 franchise. Competitively, Ovid operates in a crowded but scientifically attractive field that includes larger pharmaceutical companies and specialist neuroscience biotechs. Its relative strengths lie in target differentiation, a focused pipeline, and the potential to build a proprietary franchise around epilepsy, psychosis, and other CNS disorders. Its limitations are those typical of small-cap biotech: dependence on clinical success, regulatory approvals, and access to capital. As such, the stock carries meaningful event risk, but also meaningful upside if proof-of-concept data continue to confirm the platform. Recent milestones have been important. In 2026, Ovid reported continued pipeline progress, including Phase 1 dosing for OV4071, expansion of OV329 into complementary seizure indications, and new financing that strengthened its runway. The company has also indicated a longer cash runway and multiple anticipated clinical catalysts over the next 18 to 24 months. For investors following U.S. healthcare equities, OVID on NASDAQ offers a focused, high-risk/high-reward exposure to CNS innovation in the United States.